IGC Pharma Reaches 80% Enrollment in Phase 2 Alzheimer’s Trial for Agitation

IGC Pharma (NYSE American: IGC) has reached approximately 80% patient enrollment in its Phase 2 CALMA clinical trial, evaluating its investigational therapy IGC-AD1 for agitation in Alzheimer’s patients. The randomized, double-blind, placebo-controlled study is designed to assess both safety and efficacy as the program advances toward a key data readout.

With agitation affecting up to 76% of Alzheimer’s patients and limited treatment options available, IGC is targeting a significant unmet need in a multi-billion-dollar market. The company expects to complete enrollment by mid-2026, positioning the trial for a major milestone.

#IGCPharma
#IGC
#Alzheimers
#ClinicalTrials
#Biotech
#Neuroscience
#DrugDevelopment
#MentalHealth
#HealthcareInnovation
#MedicalResearch
#NeurodegenerativeDisease
#BiotechInvesting
#Innovation
#AnnaBerry
#NewsOut